TENAX THERAPEUTICS, INC. — Investor Relations & Filings
Filings indexed
939
across all filing types
Latest filing
2025-11-20
Director's Dealing
Country
US
United States of America
Listing
US
TENX
Tenax Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapies for cardiovascular and pulmonary diseases. The company's primary drug candidate is TNX-103, an oral formulation of levosimendan, for the treatment of heart failure. The intravenous form of levosimendan is already approved in numerous countries for acute decompensated heart failure, providing an established safety profile. Additionally, Tenax is developing a formulation of imatinib mesylate, a kinase inhibitor, for the treatment of pulmonary arterial hypertension (PAH). The company's development strategy is guided by clinical insights into cardiopulmonary disorders and is led by a management team with extensive experience in the field.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| PRIMARY DOCUMENT | 2025-11-20 | English | |
| Major Shareholding Notification 2025 | 2025-11-14 | English | |
| Major Shareholding Notification 2025 | 2025-11-14 | English | |
| Major Shareholding Notification 2025 | 2025-11-14 | English | |
| 10-Q | 2025-11-12 | English | |
| FORM 8-K | 2025-11-12 | English |
Browse filings by year
31 years- 2026 37 filings
- 2025 56 filings
- 2024 84 filings
- 2023 52 filings
- 2022 47 filings
- 2021 50 filings
- 2020 49 filings
- 2019 16 filings
- 2018 38 filings
- 2017 21 filings
- 2016 25 filings
- 2015 28 filings
- 2014 41 filings
- 2013 91 filings
- 2012 37 filings
- 2011 43 filings
- 2010 56 filings
- 2009 26 filings
- 2008 21 filings
- 2007 16 filings
- 2006 25 filings
- 2005 24 filings
- 2004 12 filings
- 2003 8 filings
- 2002 6 filings
- 2001 7 filings
- 2000 6 filings
- 1999 6 filings
- 1998 4 filings
- 1997 4 filings
- 1996 3 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 9049989 | PRIMARY DOCUMENT | 2025-11-20 | English | ||
| 8440298 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 8440299 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 8440300 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 8440301 | 10-Q | 2025-11-12 | English | ||
| 8440302 | FORM 8-K | 2025-11-12 | English | ||
| 8440303 | Major Shareholding Notification 2025 | 2025-11-05 | English | ||
| 8440304 | Major Shareholding Notification 2025 | 2025-10-29 | English | ||
| 8440305 | Major Shareholding Notification 2025 | 2025-10-07 | English | ||
| 8440306 | Major Shareholding Notification 2025 | 2025-10-02 | English | ||
| 8440307 | FORM 8-K | 2025-09-16 | English | ||
| 8440308 | FORM 8-K | 2025-09-09 | English | ||
| 8440309 | Major Shareholding Notification 2025 | 2025-08-14 | English | ||
| 8440310 | Major Shareholding Notification 2025 | 2025-08-14 | English | ||
| 8440311 | 10-Q | 2025-08-13 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
TENAX THERAPEUTICS, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34835/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34835 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34835 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34835 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34835}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for TENAX THERAPEUTICS, INC. (id: 34835)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.